Medicus Pharma announced a conference call on November 9, 2026, to review its Q3 financial results and business updates. Key topics include the new co-development and licensing agreement with Pfizer for the CD228V cancer therapy, a proposed business combination with SkinJect via a SPAC, and a concurrent financing letter of intent. The call will also cover progress on the Teverelix program and the company's strategic plans to advance its therapeutic assets through clinical milestones and partnerships. This event is important as it outlines Medicus' growth strategy and potential collaborations to enhance its biotech pipeline.
Pfizer shares are trading at USD 30.78 on Pluang as of Nov 05, 2026 04:11 WIB, up 2.60% in one day. The stock shows a dividend yield of 5.73% and a market cap of $170.99 billion. Pluang users currently lean 64% towards selling Pfizer shares, reflecting mixed sentiment ahead of Medicus Pharma's business update call.
Pfizer reported Q3 2026 revenue of $16.58 billion and adjusted EPS of $0.87, surpassing analyst expectations. The company's non-COVID product portfolio grew 7% operationally, with new and acquired products up 32%, offsetting declines in COVID-related...
Moderna's stock rose 5% ahead of its earnings report, continuing a strong 685% gain this year, driven by its mRNA vaccine focus and oncology pipeline. Pfizer's shares fell 0.8% despite beating Q3 revenue estimates and raising its 2026 guidance, as CO...
UPS paid $5.4 billion in dividends in 2025, surpassing its free cash flow of $4.8 billion, signaling potential payout risks. Similar concerns apply to Pfizer, AGNC Investment, and Kraft Heinz, where dividends outpace earnings or cash flow, threatenin...
Pfizer reported third-quarter earnings that exceeded analyst expectations, with adjusted earnings per share of 87 cents versus the expected 73 cents, and revenue of $16.58 billion beating the $15.87 billion forecast. The company raised its full-year ...
